The combination of sEH inhibition and FXR agonism have been developed and tested for beneficial actions for nonalcoholic steatohepatitis (NASH) and kidney fibrosis (Hye Khan et al., 2019; Stavniichuk et al., 2020). This evidence concerns the gene EPHX2 and metabolic dysfunction-associated steatohepatitis.